SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will webcast a conference call on Wednesday, October
31, 2007 at 8:30 a.m. ET/5:30 a.m. PT to discuss today's release of the
once-weekly exenatide long-acting release study results. Daniel M.
Bradbury, Amylin's President and Chief Executive Officer, will lead the
call.
The call will be webcast live through Amylin's corporate website and a
recording will be made available following the close of the call. To access
the webcast, please log on to http://www.amylin.com approximately fifteen
minutes prior to the call to register, download and install any necessary
audio software. For those without access to the Internet, the live call may
be accessed by phone by calling (866) 356-3095 (domestic) or (617) 597-5391
(international), passcode 19644079. A replay of the call will also be
available by phone for 24 hours beginning approximately one hour after the
close of the call and can be accessed at (888) 286-8010 (domestic) or (617)
801-6888 (international), passcode 23209035.
About Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed
to improving lives through the discovery, development and commercialization
of innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 1,800 employees
nationwide. Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Alice Bahner Izzo of Amylin Pharmaceuticals,
Inc., Executive Director, Corporate Affairs, +1-858-552-2200,
ext. 7272
|
